Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.

In the double-blind study conducted in China, Georgia, Poland, Russia, Turkey, and Ukraine, 585 patients who had not received prior systemic therapy for extensive-stage SCLC were randomly allocated to receive either intravenous serplulimab 4.5 mg/kg or placebo every 3 weeks until unacceptable toxicity, disease progression, or death, alongside up to four 3-weekly cycles of etoposide 100 mg/m 2 given on days 1–3 plus carboplatin AUC 5 on day 1.

Adding pembrolizumab to etoposide plus platinum continues to improve the outcomes of treatment-naïve people with extensive-stage small-cell lung cancer in the long term, suggest follow-up data from KEYNOTE-604.

Chemotherapy was etoposide with cisplatin or carboplatin for four to six cycles among the patients with SCLC and weekly paclitaxel with carboplatin for up to six cycles among those with NSCLC, while RT was given at a total dose of 60–63 Gy in fractions of 1.8–2.1 Gy using 3-dimensional conformal RT or intensity-modulated RT techniques.

Adding tiragolumab to atezolizumab plus carboplatin and etoposide provides no additional progression-free or overall survival benefit to patients with untreated extensive-stage small-cell lung cancer, phase 3 study data show.

After a median 13.5 months of follow-up, the phase 3 CAPSTONE-1 trial achieved a 2.5-month improvement in OS with the use of adebrelimab 20 mg/kg on day 1 of each 21-day cycle versus placebo when given alongside four to six cycles of carboplatin and etoposide, say Ying Cheng (Jilin Cancer Hospital, Changchun) and co-authors.

In the single-center, phase 2 study, 50 patients who had not received prior treatment for limited-stage SCLC were given four 3-weekly cycles of durvalumab 1500 mg (day 1) plus etoposide 100 mg/m 2 (days 1–3) and cisplatin 70 mg/m 2 (day 1), with chest RT at a dose of 52.5 Gy in 25 once-daily fractions initiated with the third cycle.

Keam  Abstract Trilaciclib (COSELA™) is a transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is approved in the USA to decrease the incidence of chemotherapy-induced myelosuppression (CIM) when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen in adults being treated for extensive-stage small cell lung cancer (ES-SCLC).

Durvalumab in combination with etoposide and either carboplatin or cisplatin had a manageable tolerability profile in patients with ES-SCLC.

Specifically, the OS rate was 17.6% for the 268 patients who received four courses of durvalumab 1500 mg alongside etoposide–platinum every 3 weeks and 5.8% among the 269 who received up to six cycles of chemotherapy alone.

Their analysis included 445 patients with metastatic GCT that had progressed after standard cisplatin–etoposide-based combination chemotherapy.

The trial included 170 treatment-naïve participants (median age 65 years, 57% women) from 22 hospitals in Scandinavia between 2014 and 2018 who each received four courses of intravenous cisplatin 75 mg/m 2 or carboplatin (AUC 5–6 mg/mL per min) on day 1, plus intravenous etoposide 100 mg/m 2 on days 1–3 of each 3-week cycle.

Combining a PD-L1 inhibitor with an etoposide–platinum chemotherapy regimen may be the optimal first-line treatment for patients with extensive-stage small-cell lung cancer, network meta-analysis findings suggest.

A progression-free survival of at least 12 months is a strong indicator of good survival outcomes at 2 years in patients with extensive-stage small-cell lung cancer taking durvalumab alongside first-line platinum–etoposide, even in those with poor prognostic factors, analysis of CASPIAN data shows.

The stage I–IIIB SCLC patients had completed four cycles of cisplatin or carboplatin plus etoposide chemotherapy with concurrent radiotherapy, followed by PCI, and all had a good ECOG performance status (PS) of 0–2.

The trial included 92 stage IIIA/B patients who had not progressed after concurrent chemotherapy with cisplatin plus etoposide or pemetrexed or carboplatin plus paclitaxel and radiotherapy at a dose of 59.4–66.6 Gy.

CASPIAN is an open-label, phase III trial investigating the addition of the PD-L1 inhibitor durvalumab, either with or without the CTLA-4 inhibitor tremelimumab, to a chemotherapy backbone comprising etoposide plus carboplatin or cisplatin, in patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

The PD-L1 inhibitor, in combination with etoposide and carboplatin or cisplatin, is now recommended for the first-line treatment of these patients.

She reported that patients who were randomly assigned to receive up to four cycles of durvalumab 1500 mg alongside etoposide plus cisplatin or carboplatin every 3 weeks had a longer time to deterioration for the global score and all subscales of the EORTC QLQ-C30 questionnaire than their counterparts given chemotherapy alone, with the differences reaching statistical significance for all the subscales.

Durvalumab has been approved by the US FDA for the first-line treatment of extensive-stage small-cell lung cancer in combination with etoposide and carboplatin or cisplatin.